{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:22:37Z","timestamp":1786112557183,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.cad.0000231481.07654.fc","type":"journal-article","created":{"date-parts":[[2006,10,26]],"date-time":"2006-10-26T04:53:30Z","timestamp":1161838410000},"page":"1227-1229","source":"Crossref","is-referenced-by-count":35,"title":["Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response"],"prefix":"10.1097","volume":"17","author":[{"given":"Vladimir","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Lapko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Wasif Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R3-15-20210203","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-15-20210203","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R6-15-20210203","first-page":"1019","article-title":"Cheson BD, editors. Clinical trials: referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab.","volume":"15","author":"Chen","year":"2001","journal-title":"Oncology"},{"issue":"11","key":"R7-15-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/sonc.2002.34053","article-title":"Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2\/neu protein and vascular endothelial growth factor","volume":"29","author":"Pegram","year":"2002","journal-title":"Semin Oncol"},{"key":"R8-15-20210203","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-15-20210203","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a stop-and-go fashion in advanced colorectal cancer","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"R10-15-20210203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R12-15-20210203","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ajhp\/62.10.1021","article-title":"Bevacizumab in combination chemotherapy for colorectal and other cancers","volume":"62","author":"Motl","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"R13-15-20210203","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1200\/JCO.2005.05.3728","article-title":"Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer","volume":"24","author":"Meyerhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"R14-15-20210203","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.cad.0000231481.07654.fc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:15:30Z","timestamp":1785942930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200611000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cad.0000231481.07654.fc","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}